Further studies building on these findings and involving larger patient cohorts should clarify whether targeting BCR signaling, for example with currently available specific small molecule inhibitors [66], has potential value as a treatment option for IPF patients. Here, BCR is linked to idiopathic pulmonary fibrosis.